GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » YoY EPS Growth

Apollon Formularies (AQSE:APOL) YoY EPS Growth : 0.00% (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Apollon Formularies's YoY EPS Growth for the quarter that ended in Jun. 2023 was 0.00%.

Apollon Formularies's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was £-0.00.


Apollon Formularies YoY EPS Growth Historical Data

The historical data trend for Apollon Formularies's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies YoY EPS Growth Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.00 - -411.76 96.55 -66.67

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.85 -150.00 - 100.00 -

Apollon Formularies YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Apollon Formularies's YoY EPS Growth for the fiscal year that ended in Dec. 2021 is calculated as:

YoY EPS Growth (A: Dec. 2021 )
=(Earnings per Share (Diluted) (A: Dec. 2021 )-Earnings per Share (Diluted) (A: Dec. 2020 ))/ | Earnings per Share (Diluted) (A: Dec. 2020 ) |
=(-0.005--0.003)/ | -0.003 |
=-66.67 %

Apollon Formularies's YoY EPS Growth for the quarter that ended in Jun. 2023 is calculated as:

YoY EPS Growth (Q: Jun. 2023 )
=(Earnings per Share (Diluted) (Q: Jun. 2023 )-Earnings per Share (Diluted) (Q: Dec. 2021 )) / | Earnings per Share (Diluted) (Q: Dec. 2021 )) |
=(-0.001--0.001)/ | -0.001 |
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

Jeff Auxier Interview with GuruFocus

By Holly LaFon Holly LaFon 08-28-2012

Sobering Findings About Student Debt

By OPM Insights Nelson Hsu 11-07-2015

FPA Capital Comments on Apollo Education

By Holly LaFon Holly LaFon 01-30-2017

5 Stocks to Avoid - January 2017

By Benjamin Clark Benjamin Clark 01-14-2017

FPA Capital Fund new buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-14-2015

FPA Capital Fund Finds Only 2 Stocks Matching Their Criteria in Q1

By Holly LaFon Holly LaFon 04-10-2013

Yacktman Funds Comments on Apollo Group

By Holly LaFon Holly LaFon 03-13-2013

Weekly Guru Bargains Highlights: APOL, GNW, BTU, NIHD, OKE

By GuruFocus GuruFocus 06-30-2012

FPA Capital Fund Q1 2013 Commentary

By Holly LaFon Holly LaFon 04-24-2013

First Pacific Advisors Buys Alcoa, Bank of America

By Tiziano Frateschi Tiziano Frateschi 10-16-2015